Huperzine a provides neuroprotection against several cell death inducers usingin vitro model systems of motor neuron cell death
- 1 March 2008
- journal article
- Published by Springer Nature in Neurotoxicity Research
- Vol. 13 (1) , 49-61
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting from the progressive loss of motor neurons in the spinal cord and brain. To date, clinically effective neuroprotective agents have not been available. The current study demonstrates for the first time that huperzine A, a potential neuroprotective agent, has the ability to protect a motor neuron-like cell line and motor neurons in spinal cord organotypic cultures from toxin-induced cell death. The neuroblastoma-spinal motor neuron fusion cell line, NSC34 and rat spinal cord organotypic cultures (OTC) were exposed to cell death inducers for 24 h or 14 d, respectively, with and without pre-treatment with huperzine A. The inducers used here include: staurosporine, thapsigargin, hydrogen peroxide (H2O2), carbonyl cyanidem-chlorophenyl hydrazone (CCCP) and L-(-)-threo-3-hydroxyaspartic acid (THA). These agents were selected as they induce apop-tosis/necrosis via mechanisms implicated in patients with generalized motor neuron disease. Cell death was determined in NSC34 cells by metabolic activity, caspase activity/expression and by nuclear morphology and in the OTCs, using immunohistochemistry and Western blot analysis. Nuclear staining of NSC34 cells revealed cell death induced by staurosporine, thapsigargin, H2O2 and CCCP. This induction was significantly reduced with 2 h pre-treatment with 10 µM huperzine A (maximum, 35% rescue; p2O2 but not with CCCP. These data were supported by the metabolic assays and caspase activity. In addition, pretreatment with huperzine A dramatically improved motor neuron survival, based on choline acetyltransferase (ChAT) expression analysis in OTCs following exposure to THA, and compared to THA-treated control cultures. These studies are currently being extended to include other inducers and with additional compounds as potential drug therapies that could be used in combination for the treatment of patients with ALS.Keywords
This publication has 36 references indexed in Scilit:
- Prolonged Effects of Poly(lactic‐co‐glycolic acid) Microsphere‐Containing Huperzine A on Mouse Memory Dysfunction Induced by ScopolamineBasic & Clinical Pharmacology & Toxicology, 2007
- Drug brain distribution following intranasal administration of Huperzine A in situ gel in ratsActa Pharmacologica Sinica, 2007
- ALS: A Disease of Motor Neurons and Their Nonneuronal NeighborsNeuron, 2006
- Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosisExperimental Neurology, 2005
- GDNF Delivery Using Human Neural Progenitor Cells in a Rat Model of ALSHuman Gene Therapy, 2005
- Linking Alterations in Tau Phosphorylation and Cleavage during Neuronal ApoptosisJournal of Biological Chemistry, 2004
- Effects of cyclin‐dependent kinase‐5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cellsJournal of Neuroscience Research, 2004
- Stereoselectivities of enantiomers of huperzine A in protection against β-amyloid25–35-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in miceNeuroscience Letters, 2002
- Huperzine A attenuates amyloid β‐peptide fragment 25‐35‐induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase‐3 activationJournal of Neuroscience Research, 2001
- Double‐blind Trial of Huperzine‐A (HUP) on Cognitive Deterioration in 314 Cases of Benign Senescent Forgetfulness, Vascular Dementia, and Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 1998